Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,266 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PATHWAYS Clear all
Withdrawn Phase 4 Interventional

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

NCT03580967
View directory record Official record
Conditions
Type2 Diabetes, Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Todd Doyle
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Depression, Aging, Stress and Heart Health Study

NCT05570721
View directory record Official record
Conditions
Menopause, Depression, Heart Disease in Women, Stress
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

NCT04064411
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
abaloparatide, abaloparatide solid microstructured transdermal system
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Not applicable Interventional

Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty

NCT02375009
View directory record Official record
Conditions
Glaucoma
Interventions
Selective laser trabeculoplasty
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
30 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

NCT02598895
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

NCT01158300
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
VEGF inhibitor PTC299
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 21, 2026, 10:33 AM EDT
Terminated Phase 1 Interventional

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

NCT06287463
View directory record Official record
Conditions
Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
Interventions
DCC-3084
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 10:33 AM EDT
Terminated Phase 1 Interventional

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

NCT02460367
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
Interventions
Docetaxel, Tergenpumatucel-L, Indoximod
Drug · Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
St Louis, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 21, 2026, 10:33 AM EDT
Completed No phase listed Observational

Changes in the Posterior Parietal Cortex - Primary Motor Cortex Pathway Induced by Motor Training

NCT00904332
View directory record Official record
Conditions
Movement Disorders, Heathly Subjects
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

NCT00004212
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, exatecan mesylate
Biological · Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 21, 2026, 10:33 AM EDT
Active, not recruiting No phase listed Observational

Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer

NCT04874493
View directory record Official record
Conditions
Oropharyngeal Carcinoma
Interventions
Electronic Health Record Review, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 10:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

NCT05703971
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
quaratusugene ozeplasmid, atezolizumab
Biological
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Lone Tree, Colorado • St Louis, Missouri • Canton, Ohio + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 10:33 AM EDT
Not listed No phase listed Observational

Assessment of Visual Function With a Portable Brain-computer Interface

NCT03760055
View directory record Official record
Conditions
Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
Interventions
nGoggle
Device
Lead sponsor
NGoggle
Industry
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 21, 2026, 10:33 AM EDT
Recruiting Phase 2 Interventional

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

NCT05593497
View directory record Official record
Conditions
High-Risk Prostate Cancer
Interventions
Capivasertib, abiraterone acetate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02617589
View directory record Official record
Conditions
Brain Cancer
Interventions
Nivolumab, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 21, 2026, 10:33 AM EDT
Recruiting Phase 1 Interventional

SW-682 in Advanced Solid Tumors

NCT06251310
View directory record Official record
Conditions
Advanced Solid Tumor, Mesothelioma, Malignant
Interventions
SW-682, Combination Therapy
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Not applicable Interventional

Trial of Neurostimulation and Blood Flow Restriction for PFPS in Active Duty

NCT04086615
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
NMES and exercise supplemented with high BFR, NMES and exercise supplemented with low BFR
Device
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 44 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Fort Campbell North, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

NCT01371617
View directory record Official record
Conditions
Primary Myelofibrosis, Fibrosis, Bone Marrow
Interventions
IPI-926
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Palo Alto, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 21, 2026, 10:33 AM EDT
Active, not recruiting Not applicable Interventional

PICU Up!: A Pilot Stepped-wedge Trial of a Multicomponent Early Mobility Intervention for Critically Ill Children

NCT03860168
View directory record Official record
Conditions
Critical Illness
Interventions
PICU Up!
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 24 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NCT05061017
View directory record Official record
Conditions
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
Interventions
Pixatimod, Nivolumab, Cyclophosphamide (low dose)
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

NCT01262118
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tasocitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
9
States / cities
Anniston, Alabama • Little Rock, Arkansas • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 21, 2026, 10:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

NCT03422679
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL
Interventions
CB-103
Drug
Lead sponsor
Cellestia Biotech AG
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Santa Monica, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 21, 2026, 10:33 AM EDT
Completed Early Phase 1 Interventional

Feasibility of Near-infrared Spectroscopy to Measure Cortical Pain Pathway (Brain) Activation During Dry Needling

NCT04170803
View directory record Official record
Conditions
Shoulder Pain, Chronic Pain, Musculoskeletal Injury
Interventions
Dry Needling, Sham Dry Needling
Device · Other
Lead sponsor
Army-Baylor University Doctoral Program in Physical Therapy
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 21, 2026, 10:33 AM EDT
Active, not recruiting No phase listed Observational

Longitudinal Evaluation of Active-Duty Personnel with Accessory Pathways (LEAD-AP)

NCT06798961
View directory record Official record
Conditions
Cardiac Death, Cardiac Death, Sudden, Wolf Parkinson White Syndrome
Interventions
Ablation, Standard of care without ablation
Procedure
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 21, 2026, 10:33 AM EDT